Pharmacyte Biotech, Inc. (PMCB) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Pharmacyte Biotech, Inc. on December 5, 2025, reporting an event that occurred on December 1, 2025. The Company is incorporated in Nevada and its common stock trades on The Nasdaq Capital Market under the symbol "PMCB."
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory listing matter rather than financial performance results.
Material Changes and Listing Status
On December 1, 2025, the Company received a written notice from Nasdaq indicating non-compliance with the minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)). The rule requires a minimum bid price of $1.00 per share. The Company failed to maintain this price for the 30 consecutive business days preceding the notice. The notice has no immediate effect on the listing or trading of the Company's stock, which will continue to trade under the symbol "PMCB."
Outlook, Management Commentary, and Risks
- Compliance Period: The Company has an initial 180-day period to regain compliance, ending on June 1, 2026.
- Compliance Criteria: To regain compliance, the closing bid price must be at least $1.00 per share for a minimum of 10 consecutive business days during the compliance period.
- Future Options: If compliance is not met by June 1, 2026, the Company may be eligible for an additional 180-day period if it meets other initial listing requirements and notifies Nasdaq of its intent to cure the deficiency, potentially via a reverse stock split.
- Delisting Risk: Failure to qualify for or succeed in a second compliance period may result in delisting. The Company retains the right to appeal such a determination.
- Management Action: Management intends to monitor the stock price and consider all options, including a reverse stock split subject to stockholder approval, though there is no assurance of success.
Key Facts for Investor Verification
- Verify the current closing bid price of PMCB to assess proximity to the $1.00 threshold.
- Monitor the Company's announcements regarding the potential implementation of a reverse stock split.
- Track the 180-day compliance deadline of June 1, 2026.
- Review subsequent filings for any updates on the Company's ability to meet the 10-day consecutive trading requirement.